DRL

Location

Vlaams Brabant

Founded

1980-09-05

Risk Signals

105 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Furniture, Catalog and Mail-Order Houses), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Recent Articles about DRL

Live alerts from global media, monitored by Business Radar

Nomura bullish on Dr. Reddy's after strong Q4; raises target price to Rs 1,575 on FY26 growth optimism |

2025-05-12 (businessupturn.com)

Nomura bullish on Dr. Reddy's after strong Q4; raises target price to Rs 1,575 on FY26 growth optimism |

Nomura has upgraded its outlook on Dr. Reddy's Laboratories, reaffirming a 'Buy' rating and raising the target price to ₹1,575, following a stronger-than-expected Q4 performance and optimistic FY26 guidance.DRL reported a net profit of ₹1,587.3 crore

Read more
Dr Reddy's clocks 16.51% increase in Q2 revenues

2024-11-06 (thehansindia.com)

Dr Reddy's clocks 16.51% increase in Q2 revenues

Y-o-y growth primarily driven by global generics revenuesQoQ growth primarily driven by generics revenues in emerging marketsPharma Services and Active Ingredients rose 16.76%Revenues from global generics surged 17.17%

Read more
Dr Reddy's Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%

2024-07-27 (business-standard.com)

Dr Reddy's Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%

DRL's growth was primarily driven by the robust performance of the global generics business, particularly in North America and India

Read more
Dr Reddy's Labs Q3 Preview: Revenue, net profit to record tepid growth on lag in domestic sales

2024-01-29 (moneycontrol.com)

Dr Reddy's Labs Q3 Preview: Revenue, net profit to record tepid growth on lag in domestic sales

Brokerages believe that DRL's commentary on its US base business and margin trend will remain the key monitorable, especially when the contribution from the generic cancer drug Revlimid is expected to gradually taper off through the coming fiscal.

Read more
DRL Q1 net profit dips slightly

(thehansindia.com)

DRL Q1 net profit dips slightly

HYDERABAD-BASED global pharma major Dr Reddy's Laboratories Ltd (DRL) has reported a 1.5 per cent decline in its net profit at Rs 571 crore in the quarter (Q1) ended June 30 of this financial year from Rs 579 crore during the same quarter last fiscal.

Read more
DRL Q1 net up 45% at Rs 663 cr; Israeli is new CEO from Aug 1 - Times of India

(indiatimes.com)

DRL Q1 net up 45% at Rs 663 cr; Israeli is new CEO from Aug 1 - Times of India

India Business News: Hyderabad: Despite price erosion due to increased competition in the US and Europe, and lower sales from PSAI (Pharmaceuticals Services and Active Ing.

Read more

Never miss a headline about DRL

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages